(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 56.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Aquestive Therapeutics's revenue in 2026 is $43,397,000.On average, 11 Wall Street analysts forecast AQST's revenue for 2026 to be $7,975,221,494, with the lowest AQST revenue forecast at $5,870,545,791, and the highest AQST revenue forecast at $10,043,296,262. On average, 7 Wall Street analysts forecast AQST's revenue for 2027 to be $11,824,785,718, with the lowest AQST revenue forecast at $8,548,758,128, and the highest AQST revenue forecast at $16,608,283,773.
In 2028, AQST is forecast to generate $21,431,066,830 in revenue, with the lowest revenue forecast at $13,689,969,310 and the highest revenue forecast at $28,310,822,372.